The peptide therapy market has exploded in recent years, driven by consumer interest in weight management, anti-aging, and performance optimization. For telehealth businesses, wellness clinics, and medical practices, this presents both an opportunity and a significant compliance challenge.
If your business discusses peptide therapies—whether on your website, social media, or in paid advertising—you need to understand how peptide marketing compliance affects every piece of content you publish. Get it wrong, and you risk losing your LegitScript certification, advertising account suspensions, and potential regulatory scrutiny.
The Short Answer: How to Discuss Peptides Compliantly
Here’s what healthcare businesses need to know upfront: you can discuss peptides, but the way you discuss them matters enormously.
Compliant peptide advertising and content generally:
- Focuses on FDA-approved products for their approved indications
- Provides factual, educational information without therapeutic claims for non-approved substances
- Avoids dosing guidance, treatment protocols, or implied promises of outcomes
- Does not promote investigational or non-approved peptides as available treatments
The line between education and promotion is where most businesses encounter problems—and where healthcare marketing compliance becomes critical.
Understanding the Regulatory Landscape
Effective peptide marketing starts with understanding the regulatory status of the specific product being discussed. FDA-approved medications, investigational peptides, and compounded preparations carry different requirements, and compounded drugs are not FDA-approved. These distinctions matter when describing treatment benefits, availability, and approval status on your website or in advertising. Before developing a campaign, healthcare businesses should verify the applicable rules and distinguish official FDA decisions from proposals, advisory recommendations, and industry headlines.
FDA-Approved vs. Investigational vs. Compounded Peptides
Not all peptides share the same regulatory status, and treating them interchangeably in your marketing is a common mistake.
- FDA-approved peptide medications have undergone rigorous clinical trials and received approval for specific indications. Semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) are examples. These can be discussed and promoted for their approved uses.
- Investigational peptides are being studied in clinical trials but have not received FDA approval. Marketing these as available treatments—or implying therapeutic benefits—creates serious compliance issues.
- Compounded peptides occupy a complex middle ground. Compounding is permitted under specific circumstances outlined in the Federal Food, Drug, and Cosmetic Act, but the rules differ based on facility type and current drug shortage status.
The 503A and 503B Distinction
Understanding the difference between 503A pharmacies and 503B outsourcing facilities is essential for peptide marketing compliance.
503A pharmacies compound medications based on individual patient prescriptions. They operate under state pharmacy board oversight and must compound in response to a valid prescription for an identified patient.
503B outsourcing facilities can compound larger quantities without patient-specific prescriptions but face stricter FDA oversight, including current Good Manufacturing Practice (cGMP) requirements.
Critically, both facility types can only compound drugs that appear on the FDA’s drug shortage list or that contain bulk drug substances on the FDA’s “503B Bulks List”—with important limitations. As of the FDA’s guidance on drug shortage compounding, shortage status can change at any time, immediately affecting what may be legally compounded.
Why Advisory Committee Recommendations Don’t Equal Authorization
A common misconception: when an FDA advisory committee makes a recommendation about a drug’s shortage status or compounding eligibility, this does not immediately change what pharmacies can legally compound.
Advisory committee recommendations inform FDA decision-making, but the FDA makes final determinations. Until the FDA officially updates a drug’s shortage status or issues formal guidance, the previous rules remain in effect.
For your marketing, this means: do not update content based on advisory committee news alone. Wait for official FDA action before changing how you discuss any peptide’s availability.
When Educational Content Becomes Promotional
This is where many healthcare businesses—and their marketing teams—run into trouble with LegitScript certification reviews.
The Three Triggers
Educational content typically crosses into problematic promotional territory when it includes:
- Benefit claims: Stating or implying therapeutic outcomes (“peptide X supports weight loss” or “patients report improved energy”)
- Dosing guidance: Providing protocols, suggested amounts, or administration instructions
- Calls to action: Inviting readers to book appointments, contact the clinic, or “learn if peptide therapy is right for you” in close proximity to peptide discussions
Examples: Factual vs. Problematic Language
Factual educational wording:
“Semaglutide is an FDA-approved GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.”
Potentially problematic wording:
“Many of our patients have experienced significant weight loss with peptide therapy. Contact us to see if semaglutide or other peptides could help you achieve your goals.”
Factual educational wording:
“BPC-157 is a synthetic peptide that has been studied in preclinical research. It is not FDA-approved for any indication.”
Potentially problematic wording:
“BPC-157 has shown promising results for gut health and tissue repair. Ask our providers about peptide protocols during your consultation.”
The difference often comes down to whether you’re stating regulatory facts or implying availability and therapeutic benefit.
What This Means for Your Marketing Channels
Peptide marketing requires a consistent approach across every channel where patients encounter your business. A carefully written service page can lose credibility if a social post, advertisement, or partner promotion makes conflicting claims. Before publishing, review how each channel describes the products you offer, their regulatory status, and the evidence supporting any stated benefits. The goal is to give patients clear, accurate information while meeting the requirements that apply to each platform.
Website Copy and Service Pages
Your service pages face the most scrutiny during LegitScript certification reviews. List only FDA-approved medications for approved indications. If you mention compounded peptides, clearly state their regulatory status and avoid therapeutic claims.
Blog Content
Educational blog posts can discuss peptide science, but maintain clear boundaries. Explain what research exists without extrapolating to treatment recommendations. Always note approval status.
Paid Advertising
Google, Meta, and other platforms enforce their own policies in addition to requiring LegitScript certification for certain healthcare categories. Peptide advertising on these platforms requires particular care—many peptides cannot be promoted at all, regardless of how the ad is worded.
Social Media
The informal nature of social media doesn’t exempt you from compliance requirements. Testimonials, before/after imagery, and casual benefit claims create the same risks as formal advertising.
Referral Partnerships
If you partner with compounding pharmacies or other providers, ensure their practices and marketing align with current regulations. Your certification status can be affected by association with non-compliant partners.
Content Review Checklist
Before publishing any peptide-related content, verify:
- Each peptide mentioned is identified by its current FDA approval status
- Approved medications are discussed only for approved indications
- No therapeutic claims are made for non-approved substances
- No dosing or protocol information is provided
- Compounding references accurately reflect current shortage status
- Calls to action are separated from discussions of non-approved peptides
- Sources are cited for any clinical or regulatory claims
- Content has been reviewed against current LegitScript standards
Frequently Asked Questions
Can we mention peptides that aren’t FDA-approved on our website?
You can mention them in genuinely educational contexts—explaining what they are, their regulatory status, and that they’re not approved for therapeutic use. You cannot promote them as available treatments or imply patients can receive them at your practice.
Will LegitScript certify a business that offers compounded peptides?
LegitScript evaluates businesses individually based on multiple factors, including what products are offered, how they’re sourced, and how they’re marketed. Offering compounded medications isn’t automatically disqualifying, but marketing them inappropriately can be. Review LegitScript’s certification standards for current requirements.
How quickly do we need to update our content when FDA guidance changes?
As soon as reasonably possible. If a peptide’s shortage status changes or FDA issues new compounding guidance, content reflecting the outdated status becomes a compliance liability. Build regular content audits into your marketing operations.
Can we share patient testimonials about peptide treatments?
Testimonials create significant risk because they typically include benefit claims and implied treatment outcomes. For FDA-approved medications, testimonials must comply with FDA guidance on promotional materials. For non-approved substances, testimonials effectively constitute promotional claims and should be avoided.
Navigate Peptide Marketing with Confidence
The regulatory landscape for peptide therapy continues to evolve rapidly. What’s compliant today may not be tomorrow—and the consequences of non-compliance include lost advertising capabilities, certification issues, and potential legal exposure.
At Bloom Consulting Agency, we help telehealth businesses, wellness clinics, and medical practices develop marketing strategies that reflect current compliance requirements. From website content audits to service page development, we understand both the regulatory environment and the practical realities of healthcare marketing.
Ready to review your peptide-related content or build a compliant marketing strategy?
Contact Bloom Consulting Agency to schedule a consultation. We’ll help you communicate effectively with patients while maintaining the compliance standards your business depends on.
This article is for informational purposes only and does not constitute legal advice. Regulatory requirements change frequently; consult qualified legal counsel and review current FDA guidance and LegitScript standards for decisions affecting your business. Last reviewed: October 2, 2026
